Pharmaceuticals

Pfizer

Salesforce

Conference Minutes

INFA

VEEV

TWTR

08391

4502

Below is Dolphin Research's Trans of $Salesforce(CRM.US) FY26 Q4 earnings call.For our earnings analysis, cf. 'Salesforce: The AI replacement thesis sweeps the field — has the SaaS leader been cast aside?'Key takeaways recap1) Q1 guidance: revenue of $11.03–11.08bn, implying reported growth of ~12–13%.Management also guides Q1 CRPO to grow ~14% YoY on a reported basis ...

ServiceNow

Informatica

Veeva Systems -CL

Sunrun

AstraZeneca PLC

AstraZeneca

Twitter

CORNERSTONE TEC

Takeda Pharmaceutical Co. Ltd.

CRM Trans: Organic rev. growth to re-accelerate in H2 FY

---

Canada Post Increases Pfizer Stake by 13.8% in Q4 to $9.7M; Pfizer Earnings Beat but Stock Dips on Concerns

Pfizer Average Price Target Cut to $28.88, Analysts Maintain Hold Rating

Pfizer Advances Planning for Phase III RSVpreF Vaccine Study in Japan

European Commission Approves Pfizer's HYMPAVZI for Hemophilia Patients

Pfizer Reports Robust Q1 Earnings, Stock Lags Behind S&P 500

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

Pfizer Clarifies Its COVID-19 Vaccine Does Not Contain Hantavirus

Pfizer released FY2026 Q1 earnings on May 5 During-Market (EST), actual revenue USD 14.45 B (forecast USD 13.8 B), actual EPS USD 0.4677 (forecast USD 0.5192)

Pfizer Focuses on Early Stage R&D Mergers and Acquisitions

Pfizer CEO Announces No Major Mergers and Acquisitions in the Coming Years

Pfizer Launches New Adult Pneumococcal Vaccine Covering 35 Serotypes

Pfizer Announces Business Development Funding of About 7 Billion USD

Pfizer Expects $700 Million Cost Savings from Phase One of Production Optimization Plan

Pfizer's First Quarter Revenue Grew 22% Operationally

Pfizer Does Not Anticipate Share Repurchases in 2026

Pfizer Invests $2.5B in Internal R&D Projects in Q1 2026

Pfizer reports first quarter Prevnar franchise revenue of $1.69 billion

Pfizer EPS in Q1 2023 was 0.75 USD

Pfizer Begins Adjusting Global Biopharmaceutical Business Commercial Organization Structure in Q1

Pfizer Predicts Full-Year Earnings Per Share

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pfizer Inc. (PFE.US) Q4 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Q3 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Q1 2025 Earnings Conference Call

Pfizer Inc. (PFE.US) Fourth Quarter 2024 Earnings Conference Call

Pfizer Inc. Pharmaceutical Company (PFE.US) 2024 Third Quarter Earnings Conference Call

SBIO

LABU

Pfizer Inc. (PFE) shares rose 1.30% to $25.66 on a challenging trading day for the market, outperforming competitors like Johnson & Johnson and Eli Lilly. Despite the gain, Pfizer remains 10.73% below its 52-week high of $28.75. The trading volume reached 40.9 million, surpassing its 50-day average of 37.8 million.

- Shares of Pfizer Inc. (PFE) increased by 1.30% to $25.66 amid a generally negative trading day for the stock market.  
- The stock remains 10.73% below its 52-week high of $28.75, reached on April 2nd, while competitors like Johnson & Johnson and Eli Lilly saw gains.  
- Trading volume for Pfizer was 40.9 million, surpassing its 50-day average of 37.8 million.

MarketWatch Automated

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Eli Lilly

Abbott Laboratories

Pfizer Inc. Stock Outperforms Competitors On Strong Trading Day

IBUY

Recent updates on blue-chip stocks show significant changes in ratings. Target Corporation has been upgraded from Neutral to Strong, while Pfizer Inc. has been downgraded from Strong to Neutral. A total of 95 stocks were reviewed, with various upgrades and downgrades reflecting institutional buying pressure and fundamental health. Investors are encouraged to review these changes as they may impact their portfolios.

- The article discusses updates to Stock Grader recommendations for 95 major blue-chip stocks based on recent data regarding institutional buying pressure and company fundamentals.  
- Several stocks were upgraded to higher ratings, while others experienced downgrades, reflecting changes in their quantitative and fundamental grades.  
- The author encourages readers to review their portfolios and consider using their proprietary stock screening tool for ongoing updates, accessible to premium service subscribers.

InvestorPlace

Target

VanEck Retail ETF

SPDR S&P Retail ETF

Amplify Online Retail ETF

Target Upgraded, Pfizer Downgraded: Updated Rankings on Top Blue-Chip Stocks

Thrivent Financial for Lutherans increased its holdings in Pfizer Inc. by 9.8% in Q4, acquiring 72,504 shares, bringing its total to 810,193 shares valued at $20.18 million. Other hedge funds also adjusted their positions in Pfizer. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and a target price of $28.84. Pfizer's recent earnings report showed a profit of $0.75 per share, exceeding expectations, and the company announced a quarterly dividend of $0.43 per share.

- Thrivent Financial for Lutherans increased its Pfizer Inc. holdings by 9.8% in Q4, owning 810,193 shares valued at approximately $20.18 million.  
- Other hedge funds like Vanguard and State Street also raised their positions, reflecting significant institutional investment in Pfizer, which is primarily owned by institutional investors at 68.36%.  
- Pfizer reported Q1 earnings of $0.75 per share, exceeding estimates, and announced a quarterly dividend of $0.43, amidst mixed investor sentiment regarding its future growth potential.

Market Beat

VG Health

State Street

Northern Trust

Legal & General Group Plc

Citigroup

HSBC Holdings Plc

HSBC

Barclays

ROYAL BANK OF CANADA

State Street® US Equity Premium Inc ETF

Northern Trust Pref Share NTRSO 4.7 Perp 01/01/25 E

CITIGROUP INC 6.250 NON CUM SER II PFD WI

HSBC 5xShortSG241213

HSBC HOLDINGS

Thrivent Financial for Lutherans Acquires 72,504 Shares of Pfizer Inc. $PFE

ALPMY

4503

Astellas Pharma Inc. will present new oncology data at the 2026 ASCO Annual Meeting, highlighting long-term outcomes and clinical applications across various cancer types. Key presentations include a 3.5-year follow-up on enfortumab vedotin for urothelial carcinoma and updates on prostate cancer treatments. Additionally, Astellas will introduce findings on fezolinetant for managing vasomotor symptoms in breast cancer patients. These presentations underscore Astellas' commitment to enhancing cancer care.

- Astellas Pharma will present 10 abstracts, including two oral presentations, at the 2026 ASCO Annual Meeting, highlighting its commitment to oncology research.  
- Key topics include the effectiveness of enfortumab vedotin combined with pembrolizumab for urothelial carcinoma and updates on fezolinetant for managing symptoms in breast cancer patients.  
- These presentations aim to enhance clinical understanding and improve treatment decision-making for various cancer types.

StockTitan

Astellas Pharma

Astellas Pharma Inc.

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 | PFE Stock News

Canada Post Corp Registered Pension Plan increased its stake in Pfizer Inc. (NYSE:PFE) by 13.8% in Q4, owning 390,128 shares valued at $9.71 million. Other institutional investors also raised their positions. Despite positive developments in Pfizer's pipeline, concerns about declining COVID sales and patent expirations persist, with the stock down 1.7%. Pfizer reported Q1 earnings of $0.75 per share, exceeding estimates, and set FY 2026 guidance at 2.800-3.000 EPS.

- Canada Post Corp Registered Pension Plan increased its holdings in Pfizer Inc. by 13.8%, owning 390,128 shares worth $9.7 million after purchasing an additional 47,286 shares in Q4.  
- Other institutional investors also increased their stakes, with Brighton Jones LLC growing its share by 1,282.4% to 666,318 shares valued at $17.7 million.  
- Despite a strong Q1 earnings report, Pfizer faces challenges related to declining COVID sales and patent expirations, impacting investor sentiment and stock performance.

United Bankshares

SEI Investments

Pfizer Inc. $PFE Stock Holdings Boosted by Canada Post Corp Registered Pension Plan

Allworth Financial LP increased its stake in Pfizer Inc. (NYSE:PFE) by 63.7% in Q4, owning 356,594 shares valued at $8.88 million. Other institutional investors also adjusted their positions in Pfizer. The company reported a Q1 EPS of $0.75, exceeding estimates, with revenue of $14.45 billion. Pfizer declared a quarterly dividend of $0.43 per share, yielding 6.8%. Despite positive developments, concerns about declining COVID sales and patent expirations persist.

- Allworth Financial LP increased its stake in Pfizer Inc. by 63.7%, owning 356,594 shares valued at $8,879,000.  
- The company reported earnings of $0.75 per share, exceeding estimates, and a revenue of $14.45 billion for the recent quarter, reflecting a year-over-year increase of 5.4%.  
- Pfizer also declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend of $1.72 and a yield of 6.8%, though concerns about declining COVID-related sales persist.

Allworth Financial LP Has $8.88 Million Stock Holdings in Pfizer Inc. $PFE

Pfizer (PFE) stock is currently valued at $25.33, reflecting a 6.84% decline over the past month and 8.16% over three months, despite an 18.70% return over the past year. Analysts suggest the stock is undervalued with a fair value of $30.62, driven by a strong oncology pipeline and potential for future growth. However, risks include underperformance in oncology growth and high debt levels. Pfizer trades at a P/E of 19.3, above the industry average, indicating valuation risks and potential upside.

- Pfizer (PFE) closed at US$25.33, showing mixed performance with a 1-year total shareholder return of 18.70%, while recent trading has seen a decline of 6.84% over 30 days.  
- The stock is considered undervalued with a fair value estimate of $30.62, reflecting concerns about growth prospects amid high debt and the performance of its oncology products.  
- Pfizer trades at a P/E of 19.3, suggesting valuation risk and potential upside depending on investor sentiment and future earnings performance.

Simplywall

Assessing Pfizer (PFE) Valuation After Recent Share Price Weakness And Oncology Growth Expectations

Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton, citing their earnings stability and inflation resilience. Pfizer provides a high dividend and strong drug pipeline, Molina is expected to recover, and Halliburton benefits from rising oil prices. However, a potential recession poses risks, although current valuations suggest limited downside.

- Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton due to their earnings stability, pricing power, and resilience against inflation.  
- Pfizer is noted for its high dividend and strong drug pipeline, Molina is expected to rebound after a challenging year, and Halliburton benefits from the recovery in oil prices.  
- While a recession could impact these stocks, their current valuations suggest that significant downside risk is already priced in.

Pfizer(PFE.US)